Why Sinovac Biotech, Burlington Stores, and ZIOPHARM Oncology Are Today's 3 Best Stocks

Mixed, but stabilizing, economic data was the name of the game today that helped push the broad-based S&P 500 (SNPINDEX: ^GSPC  ) higher, practically erasing almost all of yesterday's losses.

As per the norm, we got initial weekly jobless claims data today, which showed a less than 2% increase to a seasonally adjusted 320,000. In a perfect world, we never want to see jobless claims rise, but a figure of 320,000 appears low enough to warrant an ongoing drop in the unemployment rate.

What really seemed to invigorate investors today was a surprising 0.5% jump in leading indicators for February after a tame 0.1% rise in January, and a 0.1% decline in December. This big jump gives investors hope that the U.S economy will rebound voraciously from its early season weather-induced slump.

On the flip side, existing home sales data continues to be weak. February's data showed a decline of 0.4% to a seasonally adjusted annual rate of 4.6 million, matching economists' expectations, but also hitting their lowest levels since July 2012. Although low inventories are helping home prices, the precarious drop in mortgage originations anytime interest rates have even the slightest uptick is concerning.

Despite the mixed data, the S&P 500 pushed higher by 11.24 points (0.60%) to close at 1,872.01.

Topping the charts today was China-based infectious disease vaccine developer Sinovac Biotech (NASDAQ: SVA  ) , which jumped 17.1% after reporting its fourth-quarter results. For the quarter, Sinovac saw sales increase 17%, to $22.9 million, as it reported net income of $0.10 per share compared to a net loss of $0.08 per share in Q4 last year. By comparison, Wall Street was looking for Sinovac to report a loss of $0.01 per share, so this was a sizable beat. While sales of comparable products (e.g., hepatitis and influenza vaccines) actually fell 19% year over year, the addition of an H5N1 vaccine produced $7.2 million in revenue, which helped propel Sinovac higher. It's hard to argue against a company focused on treating infectious diseases given that so many countries around the world still lack access to these basic vaccines, but at 50 times forward earnings, much of that optimism may already be baked into Sinovac's share price.

Sticking with our theme of earnings-driven events, discount branded retail and accessories chain Burlington Stores (NYSE: BURL  ) gained 15.8% after reporting market-topping profits in the fourth quarter. Profit for the quarter dipped to $1.07 per share from $1.15 in the year-ago quarter, but handily surpassed the $1.03 per share that Wall Street expected. The results, though, were largely mixed, with comparable-store sales growing 4% during the quarter and signaling robust growth; yet, its first-quarter EPS forecast of $0.19-$0.23 in EPS bracketed a bit lower than Wall Street's forecast of $0.23 per share. Overall, I'm a bit put off by Burlington, which is valued at 21 times forward earnings, and is only forecasting same-store sales growth of 2%-3% in the upcoming year. I believe there are considerably more attractive places to put your money to work in the retail sector.

Finally, clinical-stage biopharmaceutical company ZIOPHARM Oncology (NASDAQ: ZIOP  ) jumped 11.8% following a rating initiation from Mizuho Financial Group. Mizuho, in a research note released last night, started ZIOPHARM with a buy rating and an $11 price target, implying 127% potential upside based on yesterday's close. Mizuho notes that ZIOPHARM's exclusive use of Intrexon's (NYSE: XON  ) RheoSwitch Therapeutic System for use in developing new oncology-based therapies could give it a unique advantage that may result in positive readouts this year. While ZIOPHARM's pipeline does offer promise, I remain cautious about that it only has two ongoing phase 2 clinical studies, and a number of preclinical studies. Until its pipeline becomes more mature, I'd prefer to stay on the sidelines.

Sinovac, Burlington, and ZIOPHARM all soared today, but even they could struggle to keep up with this top stock in 2014
There's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report, "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 20, 2014, at 6:40 PM, baloneyspotter wrote:

    It seems like everyday you have the same old line about "prefer to stay on the sidelines" but why even write the article? You don't even do your complete homework as you get the facts wrong as you write these 'short stories' on the fly. Ziopharm actually has 3 phase II studies, ongoing in melanoma, breast, and glioblastoma(started this year), and a still ongoing phase III clinical trial with Palifosamide in lung cancer called Matisse that is awaiting possible good results this year. Also Ziopharm will be heavily increasing their pipeline by end of year to the start of next year with new multigenic platform that no company will be able to duplicate(in my opinion). So stay tuned and brush up on your due diligence!

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2883962, ~/Articles/ArticleHandler.aspx, 11/23/2014 12:26:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement